Look back at pharma news in week to Jan 5
News flow last week was dominated by hints as to what is coming up at the prestigious JP Morgan annual healthcare conference which starts today. Elsewhere, a US court is questioning the Valeant Pharmaceuticals and Pershing Square settlement with Allergan; and Novartis has bagged another Breakthrough therapy designation for its Kisqali. Two licensing deals also attracted attention, that of AstraZeneca with ANI Pharmaceutical, and Takeda Pharmaceutical buying rights to early-stage neurodegenerative disease compounds from Denali Therapeutics.
JP Morgan preview – clues on CAR-T uptake and oncology timings
The annual JP Morgan healthcare conference is traditionally a hotbed of deal-making, and some companies are getting in on the action early – witness BioNTech’s mammoth $270 million series A round, which reportedly values the German group at up to $3 billion, noted EP Vantage, the editorial arm of the Evaluate group.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze